Literature DB >> 34118412

Discovery of a novel class of heteroaryl-pyrrolidinones as positive allosteric modulators of the muscarinic acetylcholine receptor M1.

Paul K Spearing1, Hyekyung P Cho1, Vincent B Luscombe1, Anna L Blobaum1, Olivier Boutaud1, Darren W Engers1, Alice L Rodriguez1, Colleen M Niswender2, P Jeffrey Conn2, Craig W Lindsley3, Aaron M Bender4.   

Abstract

This Letter describes the synthesis and optimization of a series of heteroaryl-pyrrolidinone positive allosteric modulators (PAMs) of the muscarinic acetylcholine receptor M1 (mAChR M1). Through the continued optimization of M1 PAM tool compound VU0453595, with a focus on replacement of the 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one with a wide variety of alternative 4,5-dihydropyrrolo-fused heteroaromatics, the generation of M1 PAMs with structurally novel chemotypes is disclosed. Two compounds from these subseries, 8b (VU6005610) and 20a (VU6005852), show robust selectivity for the M1 mAChR, and no M1 agonism. Both compounds have favorable preliminary PK profiles in vitro;8b additionally demonstrates high brain exposure in a rodent IV cassette model.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Muscarinic acetylcholine receptor; Positive allosteric modulator; Structure-activity relationship

Mesh:

Substances:

Year:  2021        PMID: 34118412      PMCID: PMC8349895          DOI: 10.1016/j.bmcl.2021.128193

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.940


  28 in total

Review 1.  Classics in Chemical Neuroscience: Xanomeline.

Authors:  Aaron M Bender; Carrie K Jones; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2017-02-13       Impact factor: 4.418

2.  Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.

Authors:  Julia N Heinrich; John A Butera; Tikva Carrick; Angela Kramer; Dianne Kowal; Tim Lock; Karen L Marquis; Mark H Pausch; Mike Popiolek; Shaiu-Ching Sun; Eugene Tseng; Albert J Uveges; Scott C Mayer
Journal:  Eur J Pharmacol       Date:  2009-01-11       Impact factor: 4.432

Review 3.  Muscarinic acetylcholine receptors: novel opportunities for drug development.

Authors:  Andrew C Kruse; Brian K Kobilka; Dinesh Gautam; Patrick M Sexton; Arthur Christopoulos; Jürgen Wess
Journal:  Nat Rev Drug Discov       Date:  2014-06-06       Impact factor: 84.694

Review 4.  Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.

Authors:  Bruce J Melancon; James C Tarr; Joseph D Panarese; Michael R Wood; Craig W Lindsley
Journal:  Drug Discov Today       Date:  2013-09-17       Impact factor: 7.851

5.  Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.

Authors:  Jerri M Rook; Masahito Abe; Hyekyung P Cho; Kellie D Nance; Vincent B Luscombe; Jeffrey J Adams; Jonathan W Dickerson; Daniel H Remke; Pedro M Garcia-Barrantes; Darren W Engers; Julie L Engers; Sichen Chang; Jarrett J Foster; Anna L Blobaum; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2017-01-10       Impact factor: 4.418

6.  PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems.

Authors:  Sean P Moran; Hyekyung P Cho; James Maksymetz; Daniel H Remke; Ryan M Hanson; Colleen M Niswender; Craig W Lindsley; Jerri M Rook; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2018-04-25       Impact factor: 4.418

7.  4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor.

Authors:  Shailesh N Mistry; Manuela Jörg; Herman Lim; Natalie B Vinh; Patrick M Sexton; Ben Capuano; Arthur Christopoulos; J Robert Lane; Peter J Scammells
Journal:  J Med Chem       Date:  2015-12-31       Impact factor: 7.446

8.  Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration.

Authors:  Joseph D Panarese; Hykeyung P Cho; Jeffrey J Adams; Kellie D Nance; Pedro M Garcia-Barrantes; Sichen Chang; Ryan D Morrison; Anna L Blobaum; Colleen M Niswender; Shaun R Stauffer; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-04-29       Impact factor: 2.823

9.  Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAM.

Authors:  Thomas M Bridges; J Phillip Kennedy; Meredith J Noetzel; Micah L Breininger; Patrick R Gentry; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2010-02-01       Impact factor: 2.823

10.  Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor with Weak Agonist Activity and Diverse Modulatory Profiles.

Authors:  Juliana C C Dallagnol; Elham Khajehali; Emma T van der Westhuizen; Manuela Jörg; Celine Valant; Alan G Gonçalves; Ben Capuano; Arthur Christopoulos; Peter J Scammells
Journal:  J Med Chem       Date:  2018-03-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.